I-001 Noha Abdelgawad
Pharmacokinetic Modelling of Rifampicin, Isoniazid, Pyrazinamide, and Linezolid in Central Nervous System: Insights from a Rabbit Model of Tuberculosis Meningitis
Wednesday 10:20-11:50 |
I-002 Kimberly Adams
Physiologically-Based Pharmacokinetic Modeling of Extended-Release MK-2048 Formulations for HIV Pre-Exposure Prophylaxis in Non-Human Primates
Wednesday 10:20-11:50 |
I-003 Katrine Agergaard
Population pharmacokinetic modelling of whole blood and intracellular tacrolimus in adult kidney transplanted patients
Wednesday 10:20-11:50 |
I-004 Jurij Aguiar Zdovc
Population pharmacokinetic-pharmacodynamic analysis of elafibranor and metabolite GFT1007 to support exposure-response characterization and dose selection in patients with primary biliary cholangitis
Wednesday 10:20-11:50 |
I-005 Ludovica Aiello
Modeling tumor growth inhibition in Glioblastoma spheroids after exposure to RC-106, a novel sigma receptors modulator
Wednesday 10:20-11:50 |
I-006 Karam Alali
Population pharmacokinetic Models of regular SC insulin for hyperglycemia following acute ischemic stroke among patients with and without pre-existing diabetes mellitus
Wednesday 10:20-11:50 |
I-007 Mahmoud Ali
mastering upset plots: a comprehensive tutorial for effective data visualization in pharmacometrics and drug development
Wednesday 10:20-11:50 |
I-008 Nikolaos Alimpertis
Leveraging the Finite Absorption Time (F.A.T.) Concept for Advancing PBPK Modeling and Pharmacometric structural models: Moving MIDD to Model Informed Drug Development and Assessment (MIDDA)
Wednesday 10:20-11:50 |
I-009 Magali Amiel
Physiologically Based Pharmacokinetic modelling of the Drug-Drug Interaction between Ivacaftor and Lefamulin in Cystic Fibrosis patients
Wednesday 10:20-11:50 |
I-010 Karkhanis Aneesh
A PBPK model of 4β-hydroxycholesterol, an endogenous biomarker for hepatic CYP3A activity.
Wednesday 10:20-11:50 |
I-011 Arkadiusz Adamiszak
Do critically ill patients undergoing continuous renal replacement therapy require ceftaroline dosage adjustments? Ceftaroline PopPK model and dosage simulations with probability of target attainment analysis based on retrospective data.
Wednesday 10:20-11:50 |
I-012 Innocent Asiimwe
The Applied Pharmacometrics Training Program – Year 3 Sustainability
Wednesday 10:20-11:50 |
I-013 Romain Aubry
Translational PKPD modelling of ceftazidime/avibactam for treatment of carbapenemase-producing Klebsiella pneumoniae in the persistently neutropenic rabbit pneumonia model
Wednesday 10:20-11:50 |
I-014 Sally Babiker
Dose rationale for bedaquiline in paediatric patients with multi drug-resistant tuberculosis
Wednesday 10:20-11:50 |
I-015 Salma Bahnasawy
Applying PKPD modelling to evaluate the impact of plasma proteins in time-kill experiments; does the protein binding matter?
Wednesday 10:20-11:50 |
I-016 Giammarco Baiardi
population pharmacokinetics and dose rationale for deferasirox in the treatment of iron overload in paediatric patients undergoing hematopoietic stem cell transplantation
Wednesday 10:20-11:50 |
I-017 Pavel Balazki
User-friendly and Quality-Controlled PBPK/QSP M&S Framework in R for Regulatory Submissions using Open Systems Pharmacology Software
Wednesday 10:20-11:50 |
I-018 Asma Baliouze
Exposure-Response Analysis of Centanafadine Sustained Release Tablets in Adults with Attention-Deficit/Hyperactivity Disorder
Wednesday 10:20-11:50 |
I-019 Annabelle Ballesta
Early morning immune checkpoint blockade and overall survival of patients with metastatic cancer: An In-depth chronotherapeutic study
Wednesday 10:20-11:50 |
I-020 Irina Baltcheva
Do more with less: Model-informed dosing rationale of iptacopan in paroxysmal nocturnal hemoglobinuria (PNH)
Wednesday 10:20-11:50 |
I-021 Enrique José Bandín Vilar
OPTIMIZATION OF THE DOSAGE REGIMEN OF LONG-ACTING INJECTABLE ARIPIPRAZOLE THROUGH MONTE CARLO SIMULATIONS
Wednesday 10:20-11:50 |
I-022 Jeff Barrett
Open-science solutions enabled within a digital research environment to support MIDD (Model Informed Drug Development) and precision dosing
Wednesday 10:20-11:50 |
I-023 Imke Bartelink
Enabling Tyrosine Kinase Inhibitor Precision Medicine through PET-Guided Physiologically-Based Pharmacokinetic Modeling
Wednesday 10:20-11:50 |
I-024 Carla Bastida Fernández
Predictive performance of published meropenem population pharmacokinetic models in critically ill adult patients.
Wednesday 10:20-11:50 |
I-025 Maxime Beaulieu
Evusheld hastens viral clearance in COVID-19 hospitalized patients: a modeling analysis of the randomized DisCoVeRy trial
Wednesday 10:20-11:50 |
I-026 Emily Behrens
External evaluation of pharmacometric models of moxifloxacin for Bayesian forecasting in the treatment of tuberculosis
Wednesday 10:20-11:50 |
I-027 Massinissa Beldjenna
Development of a multi-endpoint mechanistic pharmacokinetic-pharmacodynamic model describing CD40 antagonism in autoimmune diseases.
Wednesday 10:20-11:50 |
I-028 Salih Benamara
Development of a PBPK model to predict monoclonal antibody pharmacokinetics and bioavailability following subcutaneous administration
Wednesday 10:20-11:50 |
I-029 Amina Bensalem
Concentration-effect relationship of the sodium-glucose co-transporter 2 inhibitor dapagliflozin in healthy Beagle dogs
Wednesday 10:20-11:50 |
I-030 Martin Bergstrand
A workflow for evaluating and optimizing the designs of paediatric studies
Wednesday 10:20-11:50 |
I-031 Jan Berkhout
A model-based approach to predict SC administration and free target dynamics for monoclonal antibodies using PK and total target measurements after IV administration
Wednesday 10:20-11:50 |
I-032 Monir Bertayli
PK-PD model of morphine, pregabalin and their combination to assess the opioid-sparing effect
Wednesday 10:20-11:50 |
I-033 Daniele Boaretti
Towards an integrated mPBPK/PD model for drug-optimization and prediction of relapse after treatment of tuberculosis in mice
Wednesday 10:20-11:50 |
I-035 Rolien Bosch
From In Vitro Efficacy to Long-term HbA1c Response for GLP-1R/GlucagonR Agonism using the 4GI-HbA1c Systems Model
Wednesday 10:20-11:50 |
I-036 Chloé Bracis
Mechanisms of ART-free virus control of SHIV with AAV gene therapy delivery of eCD4Ig
Wednesday 10:20-11:50 |
I-037 Dominic Bräm
Implementation of neural ordinary differential equations in the pharmacometric software packages Monolix, NONMEM, and nlmixr
Wednesday 10:20-11:50 |
I-038 Myriam Briki
Model-based meta-analysis of individual patient data from three independent datasets for the characterization of intravenous 5-fluorouracil population pharmacokinetics
Wednesday 10:20-11:50 |
I-039 Anne Brochot
Comparison of common methodologies for accounting for IIV for oral bioavailability in the absence of intravenous data
Wednesday 10:20-11:50 |
I-040 Jordan Brooks
Steps Toward Model-Informed Precision Dosing of PEG-Asparaginase in Children and Young Adults
Wednesday 10:20-11:50 |
I-041 Divya Brundavanam
Addressing Confounding Bias in Exposure-Response Analysis: Evaluating Instrumental Variable Modeling Strategies
Wednesday 10:20-11:50 |
I-042 Divakar Budda
A comprehensive binding kinetic model for morphine in the pain matrix regions: what are the most important physiological factors for morphine µ-OR occupancy?
Wednesday 10:20-11:50 |
I-043 Nils Bundgaard
Model informed dose projection for SAB-176 using a joint time-to-event modeling approach in high-risk (HR) patients infected with Influenza
Wednesday 10:20-11:50 |
I-044 Nils Bundgaard
Framework for Polyclonal Antibody Drug Development: Integrating Trial Data and Literature Models
Wednesday 10:20-11:50 |
I-045 Nils Bundgaard
Characterization of the population dose-exposure-efficacy relationships of vamorolone, a synthetic corticosteroid drug in the treatment of Duchenne Muscular Dystrophy (DMD)
Wednesday 10:20-11:50 |
I-046 Andrew Butler
Predicting the effect of postpartum changes in breastmilk composition on the partitioning of anti-malarial medications
Wednesday 10:20-11:50 |
I-047 Andrew Butler
Exploration of CPRD and Yellow Card real-world data to support efficacy and safety targets for levonorgestrel contraceptives.
Wednesday 10:20-11:50 |
I-048 Jose Miguel Calderin Miranda
Population pharmacokinetic analysis of isoniazid in plasma and cerebrospinal fluid from adults with HIV-associated tuberculosis meningitis
Wednesday 10:20-11:50 |
I-049 Elio Campanile
Supporting the development and optimization of mRNA-encoded therapeutics through a multiscale Physiologically Based Pharmacokinetic (PBPK) platform
Wednesday 10:20-11:50 |
I-050 Kangna CAO
A mechanism-based pharmacokinetic/pharmacodynamic model for iron-regulated hematopoietic stem and progenitor cells commitment towards erythroid and megakaryocyte lineages
Wednesday 10:20-11:50 |
I-051 Zhihai Cao
Evaluating Drug Interactions Between Ritonavir and Hydrocodone: Implications From Physiologically Based Pharmacokinetic Simulation
Wednesday 10:20-11:50 |
I-052 Bibiana CARDOZO
PKPD Relationship between THC Levels and Self-Assessment of Driving Proficiency Among Cannabis Users
Wednesday 10:20-11:50 |
I-053 Adriana Castiñeiras
Population analysis of the in vivo pharmacokinetic characteristics of a letrozole sustained delivery formulation in Beagle dogs
Wednesday 10:20-11:50 |
I-054 Daniel Centanni
Pharmacometric modeling to capture the time varying pharmacokinetics of PEG-asparaginase in acute lymphoblastic leukemia: A multi-protocol analysis from Nordic and Baltic countries
Wednesday 10:20-11:50 |
I-055 Maddalena Centanni
Population pharmacodynamic characterization of automatically classified circulating tumor cells and vesicles and their relationship to survival in metastatic colorectal cancer patients
Wednesday 10:20-11:50 |
I-056 Marc Cerou
A novel drug disease model in oncology to evaluate benefit-risk balance of tusamitamab ravtansine monotherapy
Wednesday 10:20-11:50 |
I-057 Anne Chain
Population Pharmacokinetic and Exposure Response Analysis of Belzutifan in Advanced Renal Cell Carcinoma
Wednesday 10:20-11:50 |
I-059 Akshita Chawla
Comparative assessment of incretin therapies on weight loss through a model-based meta-analysis approach
Wednesday 10:20-11:50 |
I-060 Wenjun Chen
Physiologically based pharmacokinetic modeling of TLL-018 for prediction of human pharmacokinetics and in vitro-in vivo extrapolation
Wednesday 10:20-11:50 |
I-061 Lu Chen
Time-dependent pharmacokinetics of hydromethylthionine mesylate (HMTM), a tau aggregation inhibitor, in healthy volunteers and patients with Alzheimer's Disease
Wednesday 10:20-11:50 |
I-062 Chengcong CHEN
Organ-specific tumor dynamics predict survival of patients with metastatic colorectal cancer
Wednesday 10:20-11:50 |
I-063 Marylore Chenel
Physiologically-based pharmacokinetic (PBPK) modeling to predict disease effects on 5-flucytosine pharmacokinetics (PK) in the context of a switch from an immediate release (IR) to a sustained release (SR) formulation in the treatment of cryptococcal meningoencephalitis.
Wednesday 10:20-11:50 |
I-064 Limei Cheng
Using machine learning to predict longitudinal platelet counts: a methodology framework
Wednesday 10:20-11:50 |
I-065 Yi-Han Chien
Modelling framework to simulate phenotypic results of antiviral PROTACs
Wednesday 10:20-11:50 |
I-066 Maxwell Chirehwa
Designing Phase II studies for optimal Phase III dosing/regimen selection using end-to-end DETER modelling
Wednesday 10:20-11:50 |
I-067 Heather Collis
A case study of applying machine learning to improve non-invasive assessment of fibrosis stage in MASLD
Wednesday 10:20-11:50 |
I-068 Emmanuelle Comets
Modelling the dynamics of bacterial colonisation in a murine model of Urinary Tract Infections
Wednesday 10:20-11:50 |
I-069 Léa COMIN
Modelling the whole-body pharmacokinetics (WBPK) of radiolabeled glyburide in healthy volunteers
Wednesday 10:20-11:50 |
I-070 Craig Comisar
Population pharmacokinetic modeling to support dose selection of zavegepant nasal spray in pediatrics.
Wednesday 10:20-11:50 |
I-071 Bárbara Costa
Pharmacokinetic Simulation Study: Exploring Lamotrigine's Impact Across Diverse Patient Populations
Wednesday 10:20-11:50 |
I-073 Perrine Courlet
Unlocking efficiency in dose selection based on pharmacokinetic-pharmacodynamic modeling of tumor size data: Insights from Clinical Trial Simulations
Wednesday 10:20-11:50 |
I-074 Marina Cuquerella Gilabert
Impact of sampling procedure on individual pharmacokinetic parameter estimation methods
Wednesday 10:20-11:50 |
I-075 Liu Dan
Population pharmacokinetics modeling of selpercatinib and simulation to support posology in paediatric and adolescent patients
Wednesday 10:20-11:50 |
I-076 Alessandro De Carlo
PopPK-PD modelling of Carboplatin-induced myelosuppression to support therapeutic drug monitoring and dose individualization in cancer patients using Electronic Health Record Data
Wednesday 10:20-11:50 |
I-077 Miné De Kock
Semi-mechanistic PK model development of Sabestomig for Dose Selection
Wednesday 10:20-11:50 |
I-078 Robert de Mooij
A quantitative comparison of tumor sub-model variants in a minimal PBPK model for early clinical dose projections of antibody therapeutics in oncology
Wednesday 10:20-11:50 |
I-079 Giuseppe De Nicolao
A mixed effect multi-funnel model for country surveillance of antibiotic resistance: evidence from the WHO GLASS dashboard
Wednesday 10:20-11:50 |
I-081 Kristof De Vos
In vitro-in silico platform for mechanistic investigation of bile acid disposition in cultured hepatocytes
Wednesday 10:20-11:50 |
I-082 Wilbert de Witte
In-depth numerical model analysis tools to gain insight into model behavior of large-scale pharmacometric models
Wednesday 10:20-11:50 |
I-083 Oleg Demin
Exploring strategies to enhance DNAM1 signaling and inhibit the TIGIT/PVRIG axis
Wednesday 10:20-11:50 |
I-084 Oleg Demin Jr
Optimizing first-in-human dose for HPN536, a T-Cell Engager Targeting Mesothelin: comparison of MABEL PK-driven approach and mechanistic translational PK/RO/PA modeling
Wednesday 10:20-11:50 |
I-085 Abdallah Derbalah
Beyond the Liver; In Silico Screening for Tissue-Specific Oligonucleotide Delivery Receptors
Wednesday 10:20-11:50 |
I-086 Laure Deyme
Population pharmacokinetic analysis of eliglustat in pediatric patients with Gaucher disease
Wednesday 10:20-11:50 |
I-087 Alessandro Di Deo
Model-based evaluation of predictive markers of response to adalimumab in juvenile idiopathic arthritis
Wednesday 10:20-11:50 |
I-088 Giovanni Di Veroli
Bridging the gap between secondary pharmacology and hemodynamics findings via Quantitative Systems modelling
Wednesday 10:20-11:50 |
I-089 Nada Dia
Model-informed comparison of the clinical relevance of four renal function markers on meropenem target attainment in critically ill septic patients
Wednesday 10:20-11:50 |
I-090 Cheikh Diack
Ocular Pharmacodynamics of Intravitreal Faricimab in Patients With Neovascular Age-Related Macular Degeneration or Diabetic Macular Edema
Wednesday 10:20-11:50 |
I-091 Ricardo Diaz de Leon Ortega
Modelling and simulation of the effect of a permeability enhancer on the absorption of a poorly permeable compound
Wednesday 10:20-11:50 |
I-093 Aris Dokoumetzidis
Extrapolation of lung pharmacokinetics of antitubercular drugs from preclinical species to humans using PBPK modeling
Wednesday 10:20-11:50 |
I-094 Vito Dozio
Population PK and exposure-response modeling to support the design of trials with Debio 0123, a WEE1 inhibitor, in cancer patients
Wednesday 10:20-11:50 |
I-095 Vincent Duval
Pharmacokinetic/Pharmacodynamic framework to support the subcutaneous dosing regimen of nemolizumab in subjects with moderate-to-severe atopic dermatitis.
Wednesday 10:20-11:50 |
I-096 Yin Edwards
Pharmacokinetics/pharmacodynamics and exposure-response modelling of VH3810109 (N6LS) in antiretroviral therapy-naïve adults with HIV-1 from the Phase IIa BANNER Study
Wednesday 10:20-11:50 |
I-097 Jeroen Elassaiss-Schaap
Construction of IMPRES-M, a non-parametric impulse-response modeling method, in the context of varying pharmacokinetic profiles
Wednesday 10:20-11:50 |
I-098 Omar Elkayal
Anidulafungin exposure and population pharmacokinetics in critically ill patients with invasive candidiasis
Wednesday 10:20-11:50 |
I-099 Ruben Faelens
Real-world data can estimate pre-exposure prophylactic drug effect in community-acquired respiratory infection trials
Wednesday 10:20-11:50 |
I-100 Xiaoqing Fan
A Whole-body Mechanistic Physiologically-based Pharmacokinetic Modeling of Intravenous Iron
Wednesday 10:20-11:50 |
I-101 Alan Faraj
Model-based approaches to prospectively power pediatric pharmacokinetic trials with limited sample size
Wednesday 10:20-11:50 |
I-102 Ali Farnoud
A Neural Networks-assisted NLME Framework: Case Study on Modeling Platelet Counts
Wednesday 10:20-11:50 |
I-103 Aneeq Farooq
A pharmacometric model assessing the synergistic effect of bacteriophage-polymyxin combination therapy in a clinical multidrug-resistant K. pneumoniae isolate in vitro.
Wednesday 10:20-11:50 |
I-104 Aaqilah Fataar
Using Bayesian Modelling to Evaluate the Effect of a Neonatal Vancomycin Loading Dose on Therapeutic Target Attainment in a Low-Middle Income Country
Wednesday 10:20-11:50 |
I-105 Floris Fauchet
Pharmacokinetic/Pharmacodynamic framework to support the subcutaneous dosing regimen of nemolizumab in subjects with Prurigo Nodularis
Wednesday 10:20-11:50 |
I-106 Lucie FAYETTE
Using Fisher Information Matrix to predict covariate effects in forest plots and power of their relevance
Wednesday 10:20-11:50 |
I-107 Denise Feick
How can we inform human intestinal permeability with Caco-2 permeability using PK-Sim®?
Wednesday 10:20-11:50 |
I-108 Rebekka Fendt
A virtual ulcerative colitis patient population to explore combination treatments in in silico clinical trials
Wednesday 10:20-11:50 |
I-109 Matthew Fidler
nlmixr2, rxode2 and Monolix: interchangeable models using monolix2rx and babelmixr2
Wednesday 10:20-11:50 |
I-110 Sophie Fischer-Holzhausen
Development of a gestational Physiologically Based Kinetic model to predict rat dam and fetus exposure in PK-Sim/MoBi
Wednesday 10:20-11:50 |
I-111 Nuria Folguera-Blasco
Coupling Quantitative Systems Pharmacology (QSP) and ML/AI: a story of pAIns and gAIns
Wednesday 10:20-11:50 |
I-112 Thomas Frank
Automating pharmacometrics reporting using R Markdown
Wednesday 10:20-11:50 |
I-113 Aline Fuchs
Human dose prediction approach for a therapeutic monoclonal antibody for a CNS indication inferred using preclinical data including target occupancy
Wednesday 10:20-11:50 |
I-114 Laura Fuhr
Physiologically based pharmacokinetic modeling of amitriptyline and its active metabolite nortriptyline to investigate CYP2D6 and CYP2C19 mediated drug-drug and drug-gene interactions
Wednesday 10:20-11:50 |
I-115 Gastón García Orueta
Population pharmacokinetics of teicoplanin in critically ill children undergoing continuous kindey replacement therapy
Wednesday 10:20-11:50 |
I-116 María García-Cremades
Predictors of treatment outcomes in children with rifampicin-resistant tuberculosis: a global individual patient data meta-analysis
Wednesday 10:20-11:50 |
